MannKind Q2 FY26 net loss widens to $19.03 million; revenue rises 43% to $109.37 million - MNKD News | RalliesMannKind Q2 FY26 net loss widens to $19.03 million; revenue rises 43% to $109.37 million
M
MNKD• Quarterly results
- MannKind posted Q2 revenue of $109.37 million, up 43% year over year.
- Operating results swung to an operating loss of $350,000 from operating income.
- Net results turned to a loss of $19.03 million, or $0.06 per share, from net income.
Product sales and regulatory updates
- Furoscix net sales were $22.19 million.
- Afrezza net sales fell 7% to $17.02 million.
- The FDA cleared Afrezza for ages 6+.
- The Furoscix ReadyFlow autoinjector won approval and is expected to reach market in late August.
•
